About CSL Behring
CSL Behring is changing its name from ZLB Behring as part of our alignment with our parent organization, CSL Limited, a specialty biopharmaceutical company with a heritage of contributions to human health for more than 90 years. The quality, type and volume of products that CSL Behring produces are not affected by this change. The company will continue to trade as ZLB Behring in some markets until registration with regulatory authorities is complete. CSL Behring is currently in the process of notifying the respective national health authorities regarding the license transfer. No changes to product names will occur. Throughout the year, company signage, product packaging, Internet sites, e-mail addresses and promotional literature will be updated to reflect the new name.
CSL Behring is a global leader in the plasma protein biotherapeutics industry, dedicated to treating rare and serious diseases and passionate about improving the quality of life of patients throughout the world.
We trace our corporate roots back to Emil von Behring, an innovator with serum therapies who won the first Nobel Prize in Physiology and Medicine. Innovation remains a core value of the company today. CSL Behring’s comprehensive line of therapies includes:
- Plasma-derived and recombinant coagulation factors for the treatment of hemophilia, von Willebrand disease and other bleeding disorders
- Immunoglobulins for the treatment of primary immune deficiency (PID), idiopathic thrombocytopenic purpura (ITP), Guillain-Barré Syndrome (GBS) and orther disorders
- Immunoglobulins for the prevention of hemolytic disease of the newborn
- Alpha1-proteinase inhibitor for chronic A1-PI augmentation therapy in adult Alpha-1 patients with emphysema
- Immunoglobulins for the prevention of cytomegalovirus infection (CMV) in organ transplantation
- C1-INH concentrate, a plasma-derived intravenous therapy containing the protein that is missing or defective in patients with hereditary angioedema
- Treatments that inhibit the formation of blood clots
- Wound-healing agents used during major surgical procedures
- Albumin for the treatment of burns, shock, and circulatory disorders
Not all products are available in every country. For specific information on products where you live, select your country from the drop-down box above.
Our products are produced at facilities in Bern, Switzerland; Marburg, Germany; and Kankakee, Illinois, in accordance with international safety and quality standards. The company also operates ZLB Plasma, one of the world’s largest plasma collection networks throughout the United States and Germany. CSL Behring employs more than 6,000 people in 18 countries.
We are passionate about safety, quality and the customers we serve. Our extensive research and development and range of support services demonstrate our ongoing commitment to all who count on our products.